Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells, ch14.18 and Lenalidomide

Trial Profile

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells, ch14.18 and Lenalidomide

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Dinutuximab (Primary) ; Lenalidomide
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Acronyms NANT
  • Most Recent Events

    • 11 Aug 2017 Planned End Date changed from 1 Jun 2020 to 1 Nov 2020.
    • 11 Aug 2017 Planned primary completion date changed from 1 Dec 2019 to 1 May 2020.
    • 11 Aug 2017 Planned initiation date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top